文献速递血栓与止血

塞利尼索诱导的血小板减少源于抑制早期巨核细胞生成中的血小板生成素信号传导

Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis.
PubMed 文献 · Blood · 2017-06-19

塞利尼索是首个口服选择性核输出抑制剂,在2期和3期临床试验中显示广谱抗肿瘤活性,但主要不良反应为高级别血小板减少。研究通过体外、体内模型及患者样本确定塞利尼索通过阻断血小板生成素(TPO)信号及干细胞向巨核细胞分化导致血小板减少,停用塞利尼索并给予TPO激动剂可逆转。

要点

  • 塞利尼索通过阻断TPO信号和巨核细胞分化导致血小板减少。
  • 停用塞利尼索并给予TPO激动剂可逆转其诱导的血小板减少。
  • 改进的塞利尼索给药方案有助于减少血小板减少并维持化疗。

核心结论

  • 塞利尼索通过抑制TPO信号和早期巨核细胞生成导致血小板减少,停用塞利尼索并给予TPO激动剂可逆转。

研究设计与样本

  • 采用体外和体内模型及患者样本进行研究。

主要发现

  • 塞利尼索通过阻断TPO信号及干细胞向巨核细胞分化导致血小板减少。
  • 在无塞利尼索(药物假期)时给予TPO激动剂可逆转塞利尼索诱导的血小板减少。

临床怎么用

  • 作者描述了改进的塞利尼索给药方案,认为对减少患者血小板减少、使其继续化疗至关重要。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Selinexor is the first oral selective inhibitor of nuclear export compound tested for cancer treatment. Selinexor has demonstrated a safety therapy profile with broad antitumor activity against solid and hematological malignancies in phases 2 and 3 clinical trials (#NCT03071276, #NCT02343042, #NCT02227251, #NCT03110562, and #NCT02606461). Although selinexor shows promising efficacy, its primary adverse effect is high-grade thrombocytopenia. Therefore, we aimed to identify the mechanism of selinexor-induced thrombocytopenia to relieve it and improve its clinical management. We determined that selinexor causes thrombocytopenia by blocking thrombopoietin (TPO) signaling and therefore differentiation of stem cells into megakaryocytes. We then used both in vitro and in vivo models and patient samples to show that selinexor-induced thrombocytopenia is indeed reversible when TPO agonists are administered in the absence of selinexor (drug holiday). In sum, these data reveal (1) the mechanism of selinexor-induced thrombocytopenia, (2) an effective way to reverse the dose-limiting thrombocytopenia, and (3) a novel role for XPO1 in megakaryopoiesis. The improved selinexor dosing regimen described herein is crucial to help reduce thrombocytopenia in selinexor patients, allowing them to continue their course of chemotherapy and have the best chance of survival. This trial was registered at www.clinicaltrials.gov as #NCT01607905.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Machlus KR, Wu SK, Vijey P, et al. Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis. Blood. 2017. PMID: 28630120. doi:10.1182/blood-2016-11-752840

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。